Compare Inovio Pharmaceuticals Inc (INO) vs Carparts.Com Inc (PRTS) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

PRTS trades at $4.97, down 6.23% today, following a 10:1 reverse stock split effective May 26, 2026, which helped it regain Nasdaq compliance. The company reported a Q1 2026 adjusted EBITDA beat and secured a $25 million credit facility in June 2026. Revenue has declined from $676M in 2023 to $548M in 2025, with net losses widening to -$50M. Analyst sentiment is positive with 60% buy ratings, but negative cash flow and profitability metrics highlight operational challenges.

The outlook remains cautious due to persistent losses and revenue contraction, though cost-cutting and new financing provide some stability. Investment opportunity lies in potential turnaround execution and low P/S of 0.06, but risks include cash burn, competitive pressures, and reliance on external funding. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.